Skip to content

Neuronetics STIM Accounts Receivable, Credit Loss Expense (Reversal)

Accounts Receivable, Credit Loss Expense (Reversal) at other companies

ClearPoint Neuro logo
ClearPoint NeuroCLPT

Other financials

Income statement

See full
Revenue$34.5M+7.8%
Gross profit$16.2M+2.6%
Operating income-$9.0M+18.3%
Net income-$10.8M+14.9%
EPS (diluted)-$0.16+23.8%

Balance sheet

See full
Cash & equivalents$13.2M-34.7%
Total debt$85.4M+3.5%
Total equity$13.3M-62.6%
Total assets$125.4M-11.7%

Cash flow

See full
Operating cash flow-$9.4M+44.6%
CapEx$197.0K-10.0%
Free cash flow-$9.6M+44.1%

Valuation

See full
Market cap$90.46M-56.2%
Enterprise value$162.64M-42.0%
P/S0.6×-1.3×

Profitability

See full
Gross margin48%-15.6pp
Operating margin-19.4%-6.9pp
Net margin-24.5%-8.7pp
FCF margin-9.4%-4.1pp

Returns & leverage

See full
Return on equity-152.4%-1.4pp
Debt / equity6.4×+4.1×
Current ratio1.7×-0.8×

Where this comes from

Reported directly by Neuronetics in its filing.

Tagged under the XBRL concept us-gaap:ProvisionForDoubtfulAccounts.

The official record: Neuronetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Neuronetics's accounts receivable, credit loss expense (reversal).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Neuronetics's accounts receivable, credit loss expense (reversal)?
Neuronetics (STIM) reported accounts receivable, credit loss expense (reversal) of -$267K in Q1 2026.
What is the long-term trend for Neuronetics's accounts receivable, credit loss expense (reversal)?
Over 2 years (2021 to 2024), Neuronetics's accounts receivable, credit loss expense (reversal) has grown at a 64.1% compound annual growth rate (CAGR), from $763K to $2.06M.